Form 8K Pelthos Therapeutics Inc For: 14 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pelthos Therapeutics Inc (PTHS)
Pelthos Therapeutics Inc stock price live, this page displays NYSE PTHS stock exchange data. View the PTHS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pelthos Therapeutics Inc real time stock price chart below.
What Is the Pelthos Therapeutics Inc Stock Price Today?
The Pelthos Therapeutics Inc stock price today is 25.000.
What Is the Stock Symbol for Pelthos Therapeutics Inc?
The stock symbol for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTHS quote. (ISIN: US1711262048)
What Is the Pelthos Therapeutics Inc Stock Price Today?
The Pelthos Therapeutics Inc stock price today is 25.000.
What Is the Stock Symbol for Pelthos Therapeutics Inc?
The stock symbol for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTHS quote. (ISIN: US1711262048)
25.000
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.960
25.250
52 wk Range
9.000
54.290
PTHS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.96025.250
52 wk Range
9.00054.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PTHS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
57.143
Upside
+128.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 57.143
(+128.57% Upside)
Pelthos Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$6.87 badly missed forecast of -$0.54, while revenue grew 28% QoQ to $9.1M driven by ZELSUVMI prescription surge of 129%
- Operating losses improved 22% from Q3 to $12.0M; cash position stood at $18.0M as of December 31, 2025
- Stock remained stable at $24.08 in premarket despite earnings miss; delivered 51% return over past year but trades above fair value of $23.08
- Company forecasts ZELSUVMI profitability by end of 2026 through sales force expansion; analysts set price targets between $48-$75
- Key risks include ongoing financial losses, convertible debt obligations, market competition, and heavy dependence on ZELSUVMI success
Last Updated: 2026-03-19, 09:12 a/m
Read Full TranscriptEarnings
Latest Release
Mar 19, 2026
EPS / Forecast
-6.87 / -0.54
Revenue / Forecast
9.39M / --
Compare PTHS to Peers and Sector
Metrics to compare | PTHS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTHSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −3.7x | −0.5x | |
PEG Ratio | 0.03 | −0.09 | 0.00 | |
Price/Book | 2.2x | 2.6x | 2.6x | |
Price / LTM Sales | 5.0x | 9.3x | 3.2x | |
Upside (Analyst Target) | 120.0% | 164.7% | 47.8% | |
Fair Value Upside | Unlock | 3.4% | 6.7% | Unlock |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pelthos Therapeutics (PTHS) Stock Price Today?
The Pelthos Therapeutics stock price today is 25.000 USD.
What Stock Exchange Does Pelthos Therapeutics Trade On?
Pelthos Therapeutics is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Pelthos Therapeutics?
The stock symbol for Pelthos Therapeutics is "PTHS."
What Is the Pelthos Therapeutics Market Cap?
As of today, Pelthos Therapeutics market cap is 83.890M USD.
What Is Pelthos Therapeutics's Earnings Per Share (TTM)?
The Pelthos Therapeutics EPS (TTM) is -23.036.
When Is the Next Pelthos Therapeutics Earnings Date?
Pelthos Therapeutics will release its next earnings report on Jun 03, 2026.
From a Technical Analysis Perspective, Is PTHS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pelthos Therapeutics Stock Split?
Pelthos Therapeutics has split 1 times.
How Many Employees Does Pelthos Therapeutics Have?
Pelthos Therapeutics has 92 employees.
What is the current trading status of Pelthos Therapeutics (PTHS)?
As of May 02, 2026, Pelthos Therapeutics (PTHS) is trading at a price of 25.000 USD, with a previous close of 25.000 USD. The stock has fluctuated within a day range of 24.960 USD to 25.250 USD, while its 52-week range spans from 9.000 USD to 54.290 USD.
What Is Pelthos Therapeutics (PTHS) Price Target According to Analysts?
The average 12-month price target for Pelthos Therapeutics is 57.143 USD, with a high estimate of 75 USD and a low estimate of 48 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +128.57% Upside potential.
What Is the PTHS Premarket Price?
PTHS's last pre-market stock price is 25.140 USD. The pre-market share volume is 100.000, and the stock has decreased by 0.140, or 0.560%.
What Is the PTHS After Hours Price?
PTHS's last after hours stock price is 25.000 USD, the stock has decreased by -0.010, or -0.040%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.